Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Afkølede blodpladeundersøgelse "CHIPS" (CHIPS)

23. oktober 2026 opdateret af: Philip Spinella

Undersøgelse af afkølede blodplader

A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1000

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Western Australia
      • Murdoch, Western Australia, Australien, 6150
        • Fiona Stanley Hospital
      • Nedlands, Western Australia, Australien, 6009
        • Sir Charles Gairdner Hospital
    • Arizona
      • Pheonix, Arizona, Forenede Stater, 85054
        • Mayo Clinic Arizona
      • Tuscon, Arizona, Forenede Stater, 85713
        • Banner University Medical Center
    • California
      • Los Angeles, California, Forenede Stater, 90095
        • Ronald Reagan UCLA Medical Center
    • Florida
      • Gainesville, Florida, Forenede Stater, 32608
        • University of Florida
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern Memorial Hospital
      • Maywood, Illinois, Forenede Stater, 60153
        • Loyola Universtiy Medical Center
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66103
        • University of Kansas Medical Center
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536
        • University of Kentucky
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • John Hopkins
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • University of Michigan
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • University of Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic
    • North Carolina
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Wake Forest
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • University of Pittsburgh Medical Center
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02910
        • Rhode Island Hospital
    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • University of Texas Children's Medical Center
      • Dallas, Texas, Forenede Stater, 75235
        • University of Texas Medical Center Clements
      • Houston, Texas, Forenede Stater, 77030
        • Memorial Hermann Texas Medical Center
      • Houston, Texas, Forenede Stater, 77030
        • Baylor Texas Children's
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • University of Wisconsin- Madison
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Children's Hospital of Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53215
        • Aurora St. Luke's Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 sekund til 84 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
  • Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.

Exclusion Criteria:

  • Expected order for washed or volume reduced platelets
  • Patient with known anti-platelet antibodies
  • Platelet transfusion refractoriness due to anti-HLA antibodies
  • Known or suspected pregnancy
  • Previously randomized in this study
  • Conscious objection or unwillingness to receive blood products
  • Known IgA deficiency
  • Known congenital platelet disorder
  • Known congenital bleeding disorder
  • Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
  • Patients intended to receive whole blood either intra-operative or post-operative for bleeding
  • Platelet transfusion (of any type) within 24 hours prior to the date of surgery
  • Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Room Temperature Platelets

Platelets stored at 20-24 degrees Celsius

Platelets stored at 20-24 degrees Celsius

Eksperimentel: Cold Stored Platelets

Platelets stored at 1-6 degree Celsius

Platelets stored at 1-6 degree Celsius

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hemostatic Efficacy
Tidsramme: 24 hours after first study platelet transfusion

Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome.

24 hours after first study platelet transfusion

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Chest Tube Output Through 24 Hours
Tidsramme: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)

Chest tube output will be assessed by volume

24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blood Product Administration
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood

24 and 72 hours from start time of first study platelet transfusion
Transfusion Associated Adverse Events
Tidsramme: within 7 days of first study platelet transfusion

As per CDC guidelines for transfusion associated adverse events

within 7 days of first study platelet transfusion
Arterial Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion

Stroke, MI, aortic thromboic even

within 7 days of first study platelet transfusion
Venous Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion

Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram

within 7 days of first study platelet transfusion
All Cause Mortality
Tidsramme: up to 28 days

Death for any reason

up to 28 days
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

Epsilon-amino-caproic acid

24 and 72 hours from start time of first study platelet transfusion
Mechanical Ventilation
Tidsramme: up to 28 days after first study platelet transfusion

Number of participants with need for mechanical ventilation

up to 28 days after first study platelet transfusion
Length of Stay
Tidsramme: up to 28 days

ICU and hospital length of stay

up to 28 days
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement).

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Unplanned Sternal Closure Delay
Tidsramme: prior to ICU admission

Sternum left open after cardiac surgery

prior to ICU admission
Re-exploration for Bleeding
Tidsramme: 24 hours first study platelet transfusion

Return to OR after ICU admission

24 hours first study platelet transfusion
Unplanned Extracorporeal Support Post Operatively
Tidsramme: within 48 hours of first study platelet transfusion

Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion

within 48 hours of first study platelet transfusion
Morbidities After ICU Admission
Tidsramme: within 7 days of first study platelet transfusion

Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock

within 7 days of first study platelet transfusion
Measures of End Organ Injury- BUN and Creatinine
Tidsramme: within 48 hours of first study platelet transfusion worst value

If BUN, creatinine are collected clinically.- worst value

within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Lactate
Tidsramme: within 48 hours of first study platelet transfusion worst value

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Troponin
Tidsramme: within 48 hours of first study platelet transfusion.

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion.
Measures of End Organ Injury- ALT and AST
Tidsramme: within 48 hours of first study platelet transfusion.

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Philip C Spinella, MD, University of Pittsburgh
  • Studieleder: Marie E Steiner, MD, University of Minnesota
  • Studieleder: Nicole D Zantek, MD, University of Minnesota

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. oktober 2021

Primær færdiggørelse (Faktiske)

25. marts 2025

Studieafslutning (Faktiske)

21. april 2025

Datoer for studieregistrering

Først indsendt

31. marts 2021

Først indsendt, der opfyldte QC-kriterier

2. april 2021

Først opslået (Faktiske)

8. april 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CHIPS
  • W81XWH2090021 (Andet bevillings-/finansieringsnummer: DoD)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner